Seeking Alpha

Advanced Flower Capital Advances Planned Conversion to BDC to Deliver Long-Term Growth and Value Creation

WEST PALM BEACH, Fla., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Advanced Flower Capital Inc. (AFCG) (“Advanced Flower Capital”, “AFC” or the “Company”) today filed a definitive proxy statement and announced ...
Nasdaq

Bolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced Cancers

BDC-3042, a novel Dectin-2 agonistic antibody that stimulates the innate immune system, is being evaluated in a Phase 1/2 dose-escalation and expansion study in patients with a broad range of solid ...
Business Insider

Bolt Biotherapeutics to Present New Clinical Data from Completed Phase 1/2 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Solid Tumors at the ESMO Congress 2023

REDWOOD CITY, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company pioneering novel immuno-oncology therapeutics for the ...
Investing

Advanced Flower Capital Q4 2025 slides: BDC pivot expands mandate

Advanced Flower Capital Inc. (NASDAQ:AFCG) presented its fourth quarter and full year 2025 results on March 4, 2026, marking a pivotal transformation as the company completed its conversion to a ...